Skip to main content
SpringerLink
Log in
Book cover

Hematopoietic Stem Cell Transplantation pp 349–374Cite as

Nonmyeloablative Transplantation

  • Chapter

Part of the book series: Contemporary Hematology ((CH))

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Barnes DWH, Loutit JF. Treatment of murine leukaemia with x-rays and homologous bone marrow: II. Br J Haematol 1957;3:241–252.

    PubMed  CAS  Google Scholar 

  2. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979;300:1068–1073.

    PubMed  CAS  Google Scholar 

  3. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, and the Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981;304:1529–1533.

    PubMed  CAS  Google Scholar 

  4. Gale RP, Horowitz MM, Ash RC et al. Identical twin bone marrow transplants for leukemia. Ann Intern Med 1994;120:646–652.

    PubMed  CAS  Google Scholar 

  5. Maraninchi D, Gluckman E, Blaise D et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987;2:175–178.

    PubMed  CAS  Google Scholar 

  6. Kolb HJ, Schmidt C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004;103:767–776.

    PubMed  CAS  Google Scholar 

  7. Sorror ML, Maris MB, Storer B et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyelo-ablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood 2004;104:961–968.

    PubMed  CAS  Google Scholar 

  8. Radich JP, Gooley T, Sanders JE, Anasetti C, Chauncey T, Appelbaum FR. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000;6:272–279.

    PubMed  CAS  Google Scholar 

  9. Storb R. Allogeneic hematopoietic stem cell transplantation - yesterday, today, and tomorrow. Exp Hematol 2003;31:1–10.

    PubMed  Google Scholar 

  10. Or R, Shapira M Y, Resnick I et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase (comment in: Blood.2003 Jun 15;101(12):5084;author reply 5084–5; PMID: 12788790). Blood 2003;101:441–445.

    PubMed  CAS  Google Scholar 

  11. Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hemato-logic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631–637.

    PubMed  CAS  Google Scholar 

  12. Morris E, Thomson K, Craddock C et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004;104:3865–3871.

    PubMed  CAS  Google Scholar 

  13. Girgis M, Hallemeier C, Blum W et al. Chimerism and clinical outcomes of 110 unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide. Blood 2005;105:3035–3041.

    PubMed  CAS  Google Scholar 

  14. Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001;98:3595–3599.

    PubMed  CAS  Google Scholar 

  15. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390–3400.

    PubMed  CAS  Google Scholar 

  16. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3234–3241.

    PubMed  CAS  Google Scholar 

  17. Giralt S. Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years? Hematology 2005;384–389.

    Google Scholar 

  18. Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000;96:2419–2425.

    PubMed  CAS  Google Scholar 

  19. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hema-tologic diseases. Blood 1998;91:756–763.

    PubMed  CAS  Google Scholar 

  20. Lowsky R, Takahashi T, Liu YP et al. Protective conditioning for acute graft-ver-sus-host disease. N Engl J Med 2005;353:1321–1331.

    PubMed  CAS  Google Scholar 

  21. de Lima M, Anagnostopoulos A, Munsell M et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004;104:865–872.

    PubMed  CAS  Google Scholar 

  22. Baron F, Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning (Review). Leukemia 2006;20:1690–1700.

    PubMed  CAS  Google Scholar 

  23. Carvallo C, Geller N, Kurlander R et al. Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors. Blood 2004;103:1560–1563.

    PubMed  CAS  Google Scholar 

  24. Baron F, Baker JE, Storb R et al. Kinetics of engraftment in patients with hema-tologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004;104:2254–2262.

    PubMed  CAS  Google Scholar 

  25. Maris MB, Niederwieser D, Sandmaier BM et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003;102:2021–2030.

    PubMed  CAS  Google Scholar 

  26. Baron F, Storb R. Allogeneic hematopoietic cell transplantation as treatment for hema-tological malignancies: a review. Seminars in Immunopathology 2004;26:71–94.

    Google Scholar 

  27. Baron F, Maris MB, Storer BE et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005;19:822–828.

    PubMed  CAS  Google Scholar 

  28. Maris MB, Sandmaier BM, Storer BE et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant 2006;12:454–465.

    PubMed  CAS  Google Scholar 

  29. Al-Ali HK, Nehring C, Krahl R et al. Donor CD34+ cell chimerism at day 28 and chronic graft-versus-host disease (GvHD) but not high-risk cytogenetics influence outcome of allogeneic hematopoietic cell transplantation (HCT) following reduced intensity conditioning (RIC) in patients with AML and MDS. Blood 2006;108 (Part 1):165a, #547 (abstract).

    Google Scholar 

  30. Weissinger F, Sandmaier BM, Maloney DG, Bensinger WI, Gooley T, Storb R. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 2001;98:3584–3588.

    PubMed  CAS  Google Scholar 

  31. Baron F, Vanstraelen G, Beguin Y. Transfusions after nonmyeloablative or reduced-intensity conditioning regimens. Leukemia 2006;20:2081–2086.

    PubMed  CAS  Google Scholar 

  32. Hogan WJ, Maris M, Storer B et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004;103:78–84.

    PubMed  CAS  Google Scholar 

  33. Parikh CR, Schrier RW, Storer B et al. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. American Journal of Kidney Diseases 2005;45:502–509.

    PubMed  Google Scholar 

  34. Fukuda T, Hackman RC, Guthrie KA et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003;102:2777–2785.

    PubMed  Google Scholar 

  35. Chien JW, Maris MB, Sandmaier BM, Maloney DG, Storb RF, Clark JG. Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:288–296.

    PubMed  Google Scholar 

  36. Junghanss C, Boeckh M, Carter RA et al. Incidence and outcome of cytome-galovirus infections following nonmyeloablative compared with myeloabla-tive allogeneic stem cell transplantation, a matched control study. Blood 2002;99:1978–1985.

    PubMed  CAS  Google Scholar 

  37. Junghanss C, Marr KA, Carter RA et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002;8:512–520.

    PubMed  Google Scholar 

  38. Maris M, Boeckh M, Storer B et al. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol 2003;31:941–952.

    PubMed  CAS  Google Scholar 

  39. Sykes M. Mixed chimerism and transplant tolerance (Review). Immunity 2001;14:417–424.

    PubMed  CAS  Google Scholar 

  40. Devetten MP, Vose JM. Graft-versus-host disease: how to translate new insights into new therapeutic strategies (Review). Biol Blood Marrow Transplant 2004;10:815–825.

    PubMed  Google Scholar 

  41. Mohty M, Blaise D, Faucher C et al. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2005;106:4407–4411.

    PubMed  CAS  Google Scholar 

  42. Shlomchik WD, Couzens MS, Tang CB et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999;285:412–415.

    PubMed  CAS  Google Scholar 

  43. Mielcarek M, Martin PJ, Leisenring W et al. Graft-versus-host disease after non-myeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756–762.

    PubMed  CAS  Google Scholar 

  44. Couriel DR, Saliba RM, Giralt S et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004;10:178–185.

    PubMed  Google Scholar 

  45. Sorror M, Maris M, Diaconescu R, Storb R. Lessened severe graft-versus-host after “minitransplantations” (Letter to the Editor). Blood 2005;105:2614

    PubMed  CAS  Google Scholar 

  46. Aoudjhane M, Labopin M, Gorin NC et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allo-geneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005;19:2304–2312.

    PubMed  CAS  Google Scholar 

  47. Scott BL, Sandmaier BM, Storer B et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006;20:128–135.

    PubMed  CAS  Google Scholar 

  48. Mohty M, Bay JO, Faucher C et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003;102:470–476.

    PubMed  CAS  Google Scholar 

  49. Crawley C, Lalancette M, Szydlo R et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;105:4532–4539.

    PubMed  CAS  Google Scholar 

  50. Lan F, Zeng D, Higuchi M, Huie P, Higgins JP, Strober S. Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: “natural suppressor” cells. J Immunol 2001;167:2087–2096.

    PubMed  CAS  Google Scholar 

  51. Martino R, Caballero MD, Simón JA et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002;100:2243–2245.

    PubMed  CAS  Google Scholar 

  52. Kroger N, Perez-Simon JA, Myint H et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of mel-phalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004;10:698–708.

    PubMed  Google Scholar 

  53. Blaise DP, Boiron JM, Faucher C et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 2005;104:1931–1938.

    PubMed  CAS  Google Scholar 

  54. Baron F, Maris MB, Sandmaier BM et al. Graft-versus-tumor effects after allo-geneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005;23:1993–2003.

    PubMed  Google Scholar 

  55. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H, Cordonnier C, Rio B, Gratwohl A, Lange T, Al-Ali H, Storer B, Maloney D, McSweeney P, Chauncey T, Agura E, Bruno B, Maziarz RT, Petersen F, Storb R. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006;24:444–453.

    PubMed  CAS  Google Scholar 

  56. Tauro S, Craddock C, Peggs K et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005;23:9387–9393.

    PubMed  CAS  Google Scholar 

  57. Niederwieser D, Cornelissen J, Al-Ali HK et al. Hematopoietic cell transplantation after a low-dose, total-body irradiation based regimen in elderly patients with AML: a multicenter, multinational, prospective HOVON/SAKK/OSHO study. Blood 2006;108 (Part 1):100a, #321 (abstract).

    Google Scholar 

  58. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG, Chauncey TR, Storb R, Deeg HJ. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelo-genous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006;20:128–135.

    PubMed  CAS  Google Scholar 

  59. Ho AYL, Pagliuca A, Kenyon M et al. Reduced-intensity allogeneic hematopoi-etic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan and alemtuzu-mab (FBC) conditioning. Blood 2004;104:1616–1623.

    PubMed  CAS  Google Scholar 

  60. Kerbauy FR, Storb R, Hegenbart U et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia 2005;19:990–997.

    PubMed  CAS  Google Scholar 

  61. Crawley C, Szydlo R, Lalancette M et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;106:2969–2976.

    PubMed  CAS  Google Scholar 

  62. Sorror ML, Maris MB, Sandmaier BM et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005;23:3819–3829.

    PubMed  Google Scholar 

  63. Khouri IF, Lee MS, Saliba RM et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004;32:28–35.

    PubMed  CAS  Google Scholar 

  64. Schetelig J, Thiede C, Bornhauser M et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003;21:2747–2753.

    PubMed  CAS  Google Scholar 

  65. Brown JR, Kim HT, Li S et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2006;12: 1056–1064.

    PubMed  Google Scholar 

  66. Delgado J, Thomson K, Russell N et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 2006;107:1724–1730.

    PubMed  CAS  Google Scholar 

  67. Maris MB, Sandmaier BM, Storer BE et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004;104:3535–3542.

    PubMed  CAS  Google Scholar 

  68. Robinson SP, Goldstone AH, Mackinnon S et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310–4316.

    PubMed  CAS  Google Scholar 

  69. Norasetthada L, Maris MB, Sandmaier BM et al. HLA-matched related (MRD) or unrelated donor (URD) non-myeloablative hematopoietic cell transplantation (HCT) for patients (pts) with refractory and relapsed aggressive non Hodgkin lymphoma. Blood 2004;104 (Part 1):634a–635a, #2307 (abstract).

    Google Scholar 

  70. Khouri IF, Lee MS, Saliba RM et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003;21:4407–4412.

    PubMed  CAS  Google Scholar 

  71. Carella AM, Cavaliere M, Lerma E, et al. Autografting followed by nonmyeloab-lative immunosuppressive chemotherapy and allogeneic peripheral-blood hemat-opoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000;18:3918–3924.

    PubMed  CAS  Google Scholar 

  72. Maloney DG, Molina AJ, Sahebi F et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447–3454.

    PubMed  CAS  Google Scholar 

  73. Nagler A, Or R, Naparstek E, Varadi G, Slavin S. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Exp Hematol 2000;28:1096–1104.

    PubMed  CAS  Google Scholar 

  74. Dey BR, McAfee S, Sackstein R et al. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant 2001;7:604–612.

    PubMed  CAS  Google Scholar 

  75. Devine SM, Sanborn R, Jessop E et al. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Bone Marrow Transplant 2001;28:557–562.

    PubMed  CAS  Google Scholar 

  76. Escalon MP, Champlin RE, Saliba RM et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004;22:2419–2423.

    PubMed  Google Scholar 

  77. Fung HC, Cohen S, Rodriguez R et al. Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed. Biol Blood Marrow Transplant 2003;9:649–656.

    PubMed  CAS  Google Scholar 

  78. Martino R, Caballero MD, de la SJ et al. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant. Bone Marrow Transplant 2002;30:63–68.

    PubMed  CAS  Google Scholar 

  79. Feinstein LC, Sandmaier BM, Maloney DG et al. Allografting after nonmyelo-ablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. Biol Blood Marrow Transplant 2003;9:266–272.

    PubMed  Google Scholar 

  80. Baron F, Storb R, Storer BE et al. Factors associated with outcomes in allo-geneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopietic cell transplantation. J Clin Oncol 2006;24:4150–4157.

    PubMed  Google Scholar 

  81. Alyea EP, Kim HT, Ho V et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005;105:1810–1814.

    PubMed  CAS  Google Scholar 

  82. Martino R, Iacobelli S, Brand R et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006;108:836–846.

    PubMed  CAS  Google Scholar 

  83. Dreger P, Brand R, Milligan D et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lym-phocytic leukemia: a population-matched analysis. Leukemia 2005;19:1029–1033.

    PubMed  CAS  Google Scholar 

  84. Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912–2919.

    PubMed  CAS  Google Scholar 

  85. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG, Scott BL, Deeg HJ, Appelbaum FR, Storb R. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007;25:4246–4254.

    PubMed  Google Scholar 

  86. Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyelo-ablative or myeloablative regimens for treatment of lymphoma and chronic lym-phocytic leukemia. Blood 2008;111:446–452.

    PubMed  CAS  Google Scholar 

  87. Mohty M, de Lavallade H, Ladaique P et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison. Leukemia 2005;19:916–920.

    PubMed  CAS  Google Scholar 

  88. Lioure B, Delaunay J, Blaise D et al. Allogeneic stem cell transplantation (SCT) with non myeloablative conditioning regimen (NST) following intensive consolidation may be equivalent to conventional alloSCT and superior to autoSCT for patients over 50 with acute myeloid leukemia (AML) in 1st CR: first results of the AML 2001 trial. Blood 2006;108 (Part 1):99a, #319 (abstract).

    Google Scholar 

  89. Garban F, Attal M, Michallet M et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474–3480.

    PubMed  CAS  Google Scholar 

  90. O'Donnell PV, Luznik L, Jones RJ et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplanta-tion cyclophosphamide. Biol Blood Marrow Transplant 2002;8:377–386.

    PubMed  Google Scholar 

  91. Barker JN, Weisdorf DJ, Defor TE, Blazar BR, Miller JS, Wagner JE. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 2003;102:1915–1919.

    PubMed  CAS  Google Scholar 

  92. Kroger N, Shimoni A, Zagrivnaja M et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004;104:3361–3363.

    PubMed  Google Scholar 

  93. Pagel JM, Appelbaum FR, Sandmaier BM et al. 131I-anti-CD45 antibody plus fludarabine, low-dose total body irradiation and peripheral blood stem cell infusion for elderly patients with advanced acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Blood 2005;106 (Part 1):119a, #397 (abstract).

    Google Scholar 

  94. Gopal AK, Pagel JM, Rajendran JG et al. Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radiotherapy. Biol Blood Marrow Transplant 2006;12:697–702.

    PubMed  CAS  Google Scholar 

  95. van de Donk NW, Kröger N, Hegenbart U et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006;107:3415–3416.

    PubMed  Google Scholar 

  96. Riddell SR, Bleakley M, Nishida T, Berger C, Warren EH. Adoptive transfer of allogeneic antigen-specific T cells. Biol Blood Marrow Transplant 2006;12:9–12.

    PubMed  CAS  Google Scholar 

  97. Sayer HG, Kröger M, Beyer J et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003;31:1089–1095.

    PubMed  CAS  Google Scholar 

  98. van Besien K, Artz A, Smith S et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005;23:5728–5738.

    PubMed  Google Scholar 

  99. Hegenbart U, Niederwieser D, Sandmaier BM et al. Treatment for acute myel-ogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006;24:444–453.

    PubMed  CAS  Google Scholar 

  100. Corradini P, Dodero A, Zallio F et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004;22:2172–2176.

    PubMed  Google Scholar 

  101. Robinson SP, Taghipour G, Sureda A. Reduced intensity allogeneic stem cell transplantation for Hodgkin's disease. Outcome depends primarily on disease status at the time of transplantation. Blood 2004;104 (Part 1):639a, #2322 (abstract).

    Google Scholar 

  102. Peggs KS, Hunter A, Chopra R et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005;365:1934–1941.

    PubMed  Google Scholar 

  103. Alvarez I, Sureda A, Caballero MD et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006;12:172–183.

    PubMed  Google Scholar 

  104. Branson K, Chopra R, Kottaridis PD et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002;20:4022–4031.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Liège, Belgium

    Frédéric Baron

  2. Division of Clinical Research, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA

    Brenda M. Sandmaier

Authors
  1. Frédéric Baron
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brenda M. Sandmaier
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, 44 Binney Street, DFCI D1B30, Boston, MA, 02115, USA

    Robert J. Soiffer MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Baron, F., Sandmaier, B.M. (2008). Nonmyeloablative Transplantation. In: Soiffer, R.J. (eds) Hematopoietic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-438-4_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-438-4_17

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-05-3

  • Online ISBN: 978-1-59745-438-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation